A new study indicates that empagliflozin, a diabetes medication, can improve cardiac structure in people with type-2 diabetes (T2D) who also have heart disease. Results from EMPA-HEART were presented at a late-breaker session at the American Heart Association on November 11.
Empagliflozin is used to reduce glucose in patients with diabetes patients, but it turns out to also have profound cardiovascular benefits. Researchers at St. Michael’s Hospital in Toronto, Canada, are uncertain why empagliflozin (Boehringer Ingelheim) causes such a reduction in death and heart failure.
The EMPA-HEART CardioLink6 trial is the first study to investigate the effects of empagliflozin on the structure and function of the heart’s left ventricle, in people with T2D and cardiovascular disease. Increased thickness of the left ventricle is associated with heart disease and heart failure. When participants were given empagliflozin, they experienced a major regression in left ventricular mass index.
The results proved impressive, particularly as they were observed on top of excellent standard of care and were evident within a very short period. Researchers say the data offer important clues as to how empagliflozin works, and how it may prevent heart failure in people with T2D.
Source: MedicalXpress.com, November 12, 2018.